✨ Free AI Report
Indivior PLC: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Indivior PLC
Company Research

Indivior PLC: Business Overview, Financials & Competitive Analysis

Indivior is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company i...

Analyst-debate audio for Indivior PLC

AskCyborg analysts argue the bull and bear cases for Indivior PLC across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

Indivior is leveraging operational efficiency and SUBLOCADE momentum to drive profitable growth in the high-value OUD treatment...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals - Opioid Use Disorder Treatment
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Indivior PLC Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Indivior PLC Overview

Pro stress-test →

Indivior is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company is executing a strategic transformation to accelerate growth and profitability in 2026 through its Indivior Action Agenda.

Strategic Profile

Pro stress-test →

The company completed Phase I of its transformation by growing U.S. SUBLOCADE net revenue, simplifying the organization and achieving expected annual non-GAAP operating expense savings of at least $150 million. Phase II, launched January 1, 2026, focuses on accelerating U.S. SUBLOCADE dispense unit growth and net revenue while immediately accelerating adjusted EBITDA and cash flow.

Competitive Landscape

Pro stress-test →

Indivior operates in the OUD treatment pharmaceutical market competing against major pharma players offering buprenorphine and methadone formulations. Key competitors include Purdue Pharma (suboxone alternatives), Hikma Pharmaceuticals (generic buprenorphine), and emerging players in medication-assisted treatment (MAT). Indivior's SUBLOCADE (extended-release buprenorphine injection) differentiates through its once-monthly dosing convenience and clinical profile.

Industry Context

Indivior PLC operates in Specialty Pharmaceuticals - Opioid Use Disorder Treatment.

Key facts

Headquarters: Richmond, Virginia, United States · Revenue: $1.125-1.195B (2026 guidance)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Indivior PLC.

  • Shifted domicile from UK to US effective January 26, 2026, signaling strategic realignment and potential tax/operational benefits
  • Achieved S&P SmallCap 600 inclusion (December 2025), expanding institutional investor accessibility
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Announced 2026 guidance with 11% SUBLOCADE growth and 35% EBITDA growth expectations
  • January 2026Completed domicile change from UK to US parent company structure
  • +2 moreTrack every material event for Indivior PLC as it happens. Explore monitoring →
Get alerted when Indivior PLC has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SuboxoneBuprenorphine-naloxone combination for OUD treatment→MethadoneSynthetic opioid agonist for opioid dependence maintenance→Generic BuprenorphineCost-effective buprenorphine formulations→

Compare Indivior PLC with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Indivior PLC operates in Specialty Pharmaceuticals - Opioid Use Disorder Treatment. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Pharmaceuticals - Opioid Use Disorder Treatment research →
NEW · MCP server

Ask your AI assistant about Indivior PLC

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Indivior PLC and its top competitor on Cyborg Score”
“What did Indivior PLC do this quarter?”
“Is Indivior PLC a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Indivior PLC do?+
Indivior is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company i...
What is Indivior PLC's Cyborg Score?+
Indivior PLC has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Indivior PLC's main competitors?+
Named competitors include Suboxone, Methadone, Generic Buprenorphine. The full competitive landscape is in the AskCyborg report.
How can I get the full Indivior PLC research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Indivior PLC research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Indivior PLC over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Specialty Pharmaceuticals - Opioid Use Disorder Treatment research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Indivior PLC